NICHOLAS RYSER: Open Payments
NPI 1376193151 · VANCOUVER, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$689 in 38 payments from 14 companies in 2025. Trend: 2023 $1,057 · 2024 $1,294 · 2025 $689
Food & beverage: $689
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $208 |
| Madrigal Pharmaceuticals | 6 | $154 |
| GENZYME CORPORATION | 4 | $76 |
| Regeneron Healthcare Solutions, Inc. | 3 | $58 |
| Janssen Biotech, Inc. | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Celltrion USA Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| TerSera Therapeutics LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
Products named: REZDIFFRA, DUPIXENT, RINVOQ, SKYRIZI, TREMFYA, VEGZELMA, TERLIVAZ, Xermelo.
Industry payments across WA — which companies pay providers there.
